Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME

Author(s):

Novel therapies, including targeted treatments and immunotherapy, have improved response rates and survival in lung cancer brain metastases.
Advanced imaging techniques are essential for monitoring treatment efficacy and disease progression in patients.
Angiopoietin-2 (Ang-2) is a promising biomarker for assessing treatment response and guiding therapeutic decisions.
A multidisciplinary approach is crucial for optimizing treatment strategies and enhancing patient quality of life.

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

1:12 Suboptimal Response
6:42 Treatment Strategy
11:22 Response to New Therapies
14:12 Imaging for Monitoring
18:42 Role of Ang-2